1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis

Table 1 Drugs, doses and therapeutic regimens applied in the presented studies

Experimental model	Drug	Route of administration	Dose	Treatment regimen
Experimental metastasis (Fig. 1)	1-MNA	Per os in drinking water	100 mg/kg/day	Treatment initiated 7 days prior cancer transplantation and continued to the end of the experiment
Experimental metastasis (Fig. 1)	1,4-DMP	Per os in drinking water	100 mg/kg/day
Spontaneous metastasis (single drug treatment) (Fig. 2)	1-MNA	Per os in drinking water	100 mg/kg/day	Continuously from the 7th day of the experiment to the end of the experiment
Spontaneous metastasis (single drug treatment) (Fig. 2)	1,4-DMP	Per os in drinking water	100 mg/kg/day
Matrigel plugs (Fig. 3)	1-MNA	Per os in drinking water	100 mg/kg/day	Continuously starting from the day of matrigel plugs transplantation
	1,4-DMP	Per os in drinking water	100 mg/kg/day
	Cyclophosphamide	intraperitoneally	25 mg/kg/day	On days 0, 3, 5
Spontaneous metastasis (combined treatment) (Fig. 4 and 5)	1-MNA	Per os in drinking water	100 mg/kg/day	Continuously from the 1st day of the experiment to the end of the experiment
	1,4-DMP	Per os in drinking water	100 mg/kg/day
	Cyclophosphamide	Intraperitoneally	25 mg/kg/day	From the 7th day of the experiment, 3 times each week